However, although KEAP1/NRF2 dysfunction is now well known to confer resistance to chemo- and radiotherapy, the KEAP1-NFE2L2 mutational status assessment is not used to make treatment decisions in lung cancer yet. This evidence concerns the gene NFE2L2 and lung carcinoma.